Seattle Genetics, Inc. today announced updated survival data from a pivotal clinical trial of single-agent ADCETRIS in patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant showing that the median overall survival has not been reached after a 26.5 month median follow-up.
